On September 29, 2016 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") reported that a series of abstracts highlighting the latest clinical and pre-clinical data on lenvatinib mesylate (selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, product name: Lenvima/Kisplyx, "lenvatinib") and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: Halaven, "eribulin") will be presented during the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2016, taking place in Copenhagen, Denmark, from October 7 – 11 (Press release, Eisai, SEP 28, 2016, View Source [SID:SID1234515488]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
For lenvatinib, six abstract poster presentations (including health economics and outcome research data) are to be given at the meeting with the main presentations featuring the latest data from a Phase Ib trial of lenvatinib in combination with the immune checkpoint inhibitor pembrolizumab in patients with selected solid tumors as well as an analysis of the responses in specific metastases following treatment with lenvatinib from the results of the Phase III SELECT Study.
For eribulin, an abstract poster presentation on a subgroup analysis in leiomyosarcoma (LMS) patients from a Phase III study (Study 309) in patients with advanced liposarcoma (LPS) and LMS is also scheduled to be given at the meeting.
Eisai positions oncology as a key franchise area. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, and in doing so seeks to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families as well as to healthcare providers.
Major Eisai abstracts accepted for presentation at this year’s ESMO (Free ESMO Whitepaper) meeting include:
Product Abstract title and scheduled presentation date and time (local time)
Lenvatinib
Abstract No: 2038 Responses in Specific Metastases Following Treatment with Lenvatinib: Results from the Phase III SELECT Study
Poster Presentation | October 9 (Sun), 13:00-14:00
Lenvatinib
Abstract No: 1608 Phase II study of lenvatinib (LEN) in patients (pts) with RET fusion–positive adenocarcinoma of the lung
Poster Presentation | October 9 (Sun), 14:45-16:15
Lenvatinib
Abstract No: 1779 A Phase Ib Trial of lenvatinib plus pembrolizumab in patients with selected solid tumors
Poster Presentation | October 9 (Sun), 16:30-17:30
Lenvatinib
Abstract No: 2008 Lenvatinib mesilate enhanced antitumor activity of PD-1 blockade agent by potentiating a Th1 immune response
Poster Presentation | October 9 (Sun), 16:30-17:30
Lenvatinib
Abstract No: 1284 The antitumor activity of lenvatinib (LEN) in combination with everolimus (EVE) in human renal cell carcinoma (RCC) xenograft models is dependent on VEGFR and FGFR signaling
Poster Presentation | October 10 (Mon), 13:00-14:00
Lenvatinib
Abstract No: 2616 Understanding real world treatment patterns, healthcare resource utilization (HRU) and costs among metastatic renal cell carcinoma (mRCC) patients
Poster Presentation | October 9 (Sun), 13:00-14:00
Eribulin
Abstract No: 1879 Subgroup analysis in leiomyosarcoma (LMS) patients (pts) from a Phase III, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced Liposarcoma (LPS) and LMS
Poster Presentation | October 10 (Mon), 11:00-12:00
(Note) SELECT Study: Study of E7080 "LEnvatinib" in Differentiated Cancer of the Thyroid